and Mansour, A.I
Oncogene-driven non-small cell lung cancers have distinct outcomes from PD-1/PD-L1 inhibitors with higher efficacy in BRAF-mutant tumors
Our clinical decisions are guided by: The strength and quality of available evidence Individual medical and psychiatric history Safety, side-effect profiles, and long-term risk How any new approach integrates with comprehensive, whole-person care If GLP-1 medications eventually prove safe and effective for certain patients with substance use disorders, they would be considered as part of a broader, medically directed treatment plannever as a standalone quick fix. In the meantime, my advice to patients is straightforward: have this conversation with your treatment team
This matters because it demonstrates that GLP-1 medications can address both the weight retention and the metabolic dysfunction that gestational diabetes leaves behind, potentially interrupting the progression to type 2 diabetes before it starts
(Neurophorol is research-stage and investigational
A global price disparity for GLP-1 drugs The US pays far more than peer nations for the same medicationsup to 10x higherhighlighting the nations fractured pharmaceutical pricing structure and raising questions about equitable access
